A pivotal study of DPX-Survivac for the treatment of ovarian cancer patients
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Maveropepimut-S (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 05 Feb 2019 New trial record
- 29 Jan 2019 According to an IMV media release, the comapny plans to schedule a follow-up meeting with FDA to finalize the design of this pivotal trial based on ORR and DOR.